Page 465 - First Aid for the USMLE Step 1 2020, Thirtieth edition [MedicalBooksVN.com]_Neat
P. 465

Hematology and oncology   ` hematology and oncology—Pathology  Hematology and oncology   ` hematology and oncology—Pathology  SectIon III  421




                  Normocytic,            Normocytic, normochromic anemias are classified as nonhemolytic or hemolytic. The hemolytic
                  normochromic            anemias are further classified according to the cause of the hemolysis (intrinsic vs extrinsic to the
                  anemias                 RBC) and by the location of the hemolysis (intravascular vs extravascular). Hemolysis can lead to
                                          increases in LDH, reticulocytes, unconjugated bilirubin, pigmented gallstones, and urobilinogen
                                          in urine.
                   Intravascular         Findings:  haptoglobin,  schistocytes on blood smear. Characteristic hemoglobinuria,
                    hemolysis             hemosiderinuria, and urobilinogen in urine. Notable causes are mechanical hemolysis (eg,
                                          prosthetic valve), paroxysmal nocturnal hemoglobinuria, microangiopathic hemolytic anemias.
                   Extravascular         Mechanism: macrophages in spleen clear RBCs. Findings: spherocytes in peripheral smear
                    hemolysis             (most commonly due to hereditary  spherocytosis and autoimmune hemolytic anemia), no
                                          hemoglobinuria/hemosiderinuria. Can present with urobilinogen in urine.



                  Nonhemolytic, normocytic anemias
                                         deScRIPtIon                              FIndIngS
                   Anemia of chronic     Inflammation (eg,  IL-6) Ž  hepcidin    iron,  TIBC,  ferritin.
                    disease               (released by liver, binds ferroportin on   Normocytic, but can become microcytic.
                                          intestinal mucosal cells and macrophages,   Treatment: address underlying cause of
                                          thus inhibiting iron transport) Ž  release of   inflammation, judicious use of blood
                                          iron from macrophages and  iron absorption   transfusion, consider erythropoiesis-
                                          from gut. Associated with conditions such   stimulating agents such as EPO (eg, in chronic
                                          as chronic infections, neoplastic disorders,   kidney disease).
                                          chronic kidney disease, and autoimmune
                                          diseases (eg, SLE, rheumatoid arthritis).
                   Aplastic anemia       Caused by failure or destruction of       reticulocyte count,  EPO.
                    A                     hematopoietic stem cells due to:        Pancytopenia characterized by anemia,
                                             ƒ Radiation and drugs (eg, benzene,   leukopenia, and thrombocytopenia (not to be
                                            chloramphenicol, alkylating agents,    confused with aplastic crisis, which causes
                                            antimetabolites)                       anemia only). Normal cell morphology,
                                             ƒ Viral agents (eg, EBV, HIV, hepatitis viruses)  but hypocellular bone marrow with fatty
                                             ƒ Fanconi anemia (autosomal recessive DNA   infiltration  A  (dry bone marrow tap).
                                            repair defect Ž bone marrow failure);   Symptoms: fatigue, malaise, pallor, purpura,
                                            normocytosis or macrocytosis on CBC    mucosal bleeding, petechiae, infection.
                                             ƒ Idiopathic (immune mediated, 1° stem cell   Treatment: withdrawal of offending
                                            defect); may follow acute hepatitis    agent, immunosuppressive regimens (eg,
                                                                                   antithymocyte globulin, cyclosporine), bone
                                                                                   marrow allograft, RBC/platelet transfusion,
                                                                                    bone marrow stimulation (eg, GM-CSF).




























          FAS1_2019_10-HemaOncol.indd   421                                                                             11/7/19   5:05 PM
   460   461   462   463   464   465   466   467   468   469   470